The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter phase II study of low-dose erlotinib in frail patients with EGFR mutation-positive, non-small cell lung cancer: Thoracic oncology research group (TORG) trial 1425.
 
Kazuhiko Yamada
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Sharp & Dohme; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Lilly Japan (Inst)
 
Shingo Miyamoto
No Relationships to Disclose
 
Koichi Azuma
No Relationships to Disclose
 
Hidenobu Ishii
No Relationships to Disclose
 
Akihiro Bessho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie; AstraZeneca; Kyorin; Pfizer; Toyama Chemical Co
 
Nobuaki Fukamatsu
No Relationships to Disclose
 
Hideo Kunitoh
No Relationships to Disclose
 
Mari Ishii
No Relationships to Disclose
 
Hiroshi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Merck Serono; MSD Oncology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiromi Aono
No Relationships to Disclose
 
Yoshiro Nakahara
Honoraria - Asahi Kasei; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Meiji Seika Kaisha; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - SRL Diagnostics
 
Kei Kusaka
No Relationships to Disclose
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Norihiro Kikuchi
No Relationships to Disclose
 
Yoshiaki Mori
No Relationships to Disclose
 
Hidetoshi Itani
Honoraria - AstraZeneca Japan; Chugai/Roche; MSD
 
Takashi Kasai
Honoraria - AstraZeneca Japan; AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; Merck Sharp & Dohme; Merck Sharp & Dohme; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Masao Ichiki
No Relationships to Disclose
 
Nobuhiko Seki
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly Japan; MSD Oncology; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim
 
Hiroaki Okamoto
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)